Aurobindo Pharma Shares Dip on Weak Outlook

  Published 1 year ago

Aurobindo Pharma shares fell over 2% after reporting a slight Q4 profit dip and forecasting flat FY26 margins. Concerns center around Revlimid competition, plant delays, and subsequent analyst downgrades and lowered estimates.

  • Q4 profit declined; FY26 margins flat.
  • Revlimid sales are expected to decrease.
  • Analysts cut price targets & downgraded.

You might like these

Gold Eases Amidst Trade Deal Hopes

Blue Cloud Acquires 3P Vision

Medi Assist Raises ₹198 Cr Share Issue

Govt Boosts Farmers' Digital Access

JB Pharma Q1 Profit, Margin Climb

CEAT Q1 Margins Fall, Expansion Planned

Maharashtra Excise Duty Hike: Winners and Losers in Liquor Market

News that matters the most ⚡